FY2027 Earnings Estimate for PCRX Issued By Zacks Research

Pacira BioSciences, Inc. (NASDAQ:PCRX) – Equities research analysts at Zacks Research issued their FY2027 earnings per share estimates for shares of Pacira BioSciences in a note issued to investors on Thursday, March 20th. Zacks Research analyst R. Department expects that the company will post earnings of $2.45 per share for the year. The consensus estimate for Pacira BioSciences’ current full-year earnings is $2.41 per share.

Other research analysts have also issued research reports about the stock. HC Wainwright boosted their price objective on shares of Pacira BioSciences from $57.00 to $70.00 and gave the stock a “buy” rating in a research note on Friday, February 28th. Needham & Company LLC upped their price target on Pacira BioSciences from $30.00 to $32.00 and gave the stock a “buy” rating in a research report on Friday, February 28th. Truist Financial raised Pacira BioSciences from a “sell” rating to a “hold” rating and raised their price objective for the stock from $8.00 to $25.00 in a research report on Thursday, January 30th. Barclays upped their target price on Pacira BioSciences from $17.00 to $24.00 and gave the company an “overweight” rating in a research report on Friday, February 28th. Finally, Royal Bank of Canada restated a “sector perform” rating and set a $18.00 price target on shares of Pacira BioSciences in a research note on Tuesday, January 14th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $27.22.

Pacira BioSciences Price Performance

PCRX opened at $24.54 on Monday. The firm has a market capitalization of $1.14 billion, a PE ratio of -12.09 and a beta of 0.86. The company has a debt-to-equity ratio of 0.51, a current ratio of 2.25 and a quick ratio of 1.89. The business’s 50-day moving average is $24.60 and its two-hundred day moving average is $19.76. Pacira BioSciences has a 1 year low of $11.16 and a 1 year high of $31.67.

Hedge Funds Weigh In On Pacira BioSciences

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Sterling Capital Management LLC raised its holdings in shares of Pacira BioSciences by 779.4% during the fourth quarter. Sterling Capital Management LLC now owns 1,363 shares of the company’s stock worth $26,000 after purchasing an additional 1,208 shares during the last quarter. Ancora Advisors LLC acquired a new position in shares of Pacira BioSciences in the 4th quarter valued at about $26,000. Caitlin John LLC boosted its stake in shares of Pacira BioSciences by 1,850.0% in the fourth quarter. Caitlin John LLC now owns 1,872 shares of the company’s stock worth $35,000 after buying an additional 1,776 shares during the last quarter. Nisa Investment Advisors LLC grew its holdings in Pacira BioSciences by 495.3% during the fourth quarter. Nisa Investment Advisors LLC now owns 3,304 shares of the company’s stock worth $62,000 after acquiring an additional 2,749 shares during the period. Finally, PNC Financial Services Group Inc. lifted its holdings in Pacira BioSciences by 16.6% in the fourth quarter. PNC Financial Services Group Inc. now owns 3,597 shares of the company’s stock valued at $68,000 after acquiring an additional 513 shares during the period. Institutional investors and hedge funds own 99.73% of the company’s stock.

Pacira BioSciences Company Profile

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.